Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy

This study compared disease outcomes, treatments, and dose reductions in patients undergoing first-line treatment with targeted therapy or immune checkpoint inhibitor therapy (immunotherapy) for metastatic renal cell carcinoma (RCC) according to age. Patients aged ≥75 years had a longer time from diagnosis to start of treatment with targeted therapy than those aged <65 years and […]

read more

Targeted therapy dose reduction resulted in better clinical outcomes

A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020. During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the […]

read more
Showing all 2 results